A study by researchers at the University of California, Riverside and UC Irvine reviewed 341 pivotal trials conducted from 2017 to 2023. The authors found that only a small share of the trials reflect the United States racial and ethnic makeup, with Black and Hispanic people increasingly underrepresented after 2021. Asian representation rose during the period, while white participation remained largely stable.
The researchers explain that many pivotal trials follow International Council for Harmonisation (ICH) standards and are run across a few regions such as the US, Europe, China and Japan, which concentrates evidence in those places. Sub-Saharan Africa and much of Latin America host very few pivotal trials and are often left out of the data that shapes medicines for Americans.
The paper, published in Communications Medicine, recommends more diversity earlier in drug development, including setting diversity goals, choosing testing locations to reflect local health needs and collecting biological samples to study drug responses.
Difficult words
- pivotal — very important for the result or decision
- underrepresent — to show fewer people than existunderrepresented
- representation — presence of people from different groups
- harmonisation — making rules or standards the same
- diversity — variety of different people or elements
- collect — to bring together items or informationcollecting
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Related articles
Coartem Baby: first malaria medicine for newborns
Swissmedic approved Coartem Baby in July 2025, the first antimalarial made for newborns under five kilograms. The tablet aims to close a long treatment gap in malaria-endemic parts of Sub-Saharan Africa.
Time of day may affect glioblastoma chemotherapy
New research finds that daily cycles of the DNA repair enzyme MGMT change during the day and may alter how glioblastoma responds to temozolomide. Biopsy timing and chronotherapy testing are next steps.
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Study finds Abbott-Bioline malaria test gives many false negatives
A study on the Thailand–Myanmar border found the Abbott-Bioline rapid malaria test missed many infections. Researchers call it “not fit for purpose”; WHO and the manufacturer are reviewing the test and further studies are under way.
Wearable 10‑Minute Antibody Sensors from University of Pittsburgh
Researchers at the University of Pittsburgh made a wearable biosensor that detects antibodies in interstitial fluid in 10 minutes without a blood draw. The tiny carbon nanotube sensors are highly sensitive and the work appears in Analytical Chemistry.
Why African Men Should Get Tested for Prostate Cancer
Prostate cancer is a major health issue for African men. Early testing can help improve survival rates.